Literature DB >> 33267788

Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019.

T J Steiner1,2, L J Stovner3,4, R Jensen5, D Uluduz6, Z Katsarava7,8,9,10.   

Abstract

Entities:  

Year:  2020        PMID: 33267788      PMCID: PMC7708887          DOI: 10.1186/s10194-020-01208-0

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


× No keyword cloud information.
The capstone papers on the Global Burden of Disease study 2019 (GBD2019), delayed by a diversion of resources to mapping covid-19, appeared in Lancet on October 17th. The accompanying announcement by the Institute for Health Metrics and Evaluation (IHME) described GBD2019 as “the largest and most comprehensive effort to quantify health loss across places and over time”, including “more than 3.5 billion estimates of … 369 diseases and injuries … in 204 countries and territories” [1]. IHME had previously announced its move to a 3-year cycle of major model updates for most non-fatal causes and risk factors (but not causes of death) [2]. Each future GBD round will include a subset of these “in rotation”, while still producing results each year for all causes of death and all non-fatal outcomes. The focus among the capstone papers was therefore on disability-adjusted life years (DALYs) [3], without the usual separately reported estimates of years lived with disability (YLDs). From a policy perspective (GBD’s main purpose is to inform health policy), this makes complete sense: years of healthy life lost to early mortality are clearly no less important than those lost to disability. But the approach takes away the spotlight from disabling diseases that do not cause early death – such as headache disorders. Nevertheless, headache disorders in 2019 ranked 14th among global causes of DALYs (all ages, both genders) [3]. Seven non-communicable disorders were ranked higher: ischaemic heart disease, stroke, chronic obstructive pulmonary disease, diabetes, low back pain, congenital defects and depressive disorders [3]. Among females, headache disorders were tenth, below gynaecological diseases (ninth) but above depressive disorders (11th). Among young adult females (15–49 years), they were second only to gynaecological diseases (note that this was of DALYs, not YLDs). Among young adult men they were tenth, with road injuries, self-harm, interpersonal violence and cirrhosis – all causes of premature mortality – each responsible for more DALYs. What about YLDs? In separate on-line estimates, headache disorders were the cause in 2019 of 46.6 million YLDs globally, 5.4% of total YLDs, with 88.2% of these attributable to migraine [4]. In terms of lost healthy life, that equates to 46.6 million people dying one year early. In the ranked causes of YLDs (all ages, both genders), headache disorders (602.5 per 100,000 person/years) were third, below low back pain (823.0) and, by a tiny margin, depressive orders (605.7) (Table 1). Among females, gynaecological diseases (second: 764.0) overtook both headache (third: 751.0) and depressive disorders (fourth: 743.7) (Table 1) despite their clearly evident association with female gender. Also clearly evident was the association of headache disorders with age – specifically, with young adulthood. Among females aged 15–49 years, headache disorders (1016.1) were second only to gynaecological diseases (1230.5), with depressive disorders third (890.4). But in all young adults, with gynaecological diseases a factor among only half, headache disorders (813.4) were top cause of YLDs (Table 1).
Table 1

GBD2019: Top level-3 causes of global disability (expressed as years lived with disability [YLDs]) by gender and age (data from [3, 4])

GenderAge range (years)RankCause% of total YLDs [uncertainty interval]
BothAll1Low back pain7.4 [6.2–8.7]
2Depressive disorders5.5 [4.3–6.8]
3Headache disorders5.4 [1.1–10.6]
15–491Headache disorders8.0 [1.6–15.7]
2Low back pain7.6 [6.1–9.3]
3Depressive disorders7.3 [5.7–9.2]
MaleAll1Low back pain7.0 [5.8–8.2
2Age-related hearing loss5.2 [4.3–6.4]
3Diabetes4.9 [4.2–5.7]
4Depressive disorders4.7 [3.7–5.9]
5Headache disorders4.6 [1.0–9.0]
15–491Low back pain7.8 [6.3–9.6]
2Headache disorders7.0 [1.5–13.8]
3Depressive disorders6.6 [5.2–8.3]
FemaleAll1Low back pain7.7 [6.5–9.2]
2Gynaecological diseases6.2 [5.1–7.3]
3Headache disorders6.0 [1.2–12.0]
4Depressive disorders6.0 [4.8–7.5]
15–491Gynaecological diseases10.7 [8.7–12.9]
2Headache disorders8.7 [1.6–16.2]
3Depressive disorder7.8 [6.0–9.9]
GBD2019: Top level-3 causes of global disability (expressed as years lived with disability [YLDs]) by gender and age (data from [3, 4]) There were variations according to World Bank region and country income level. Headache disorders were third cause of YLDs in East Asia & Pacific and in Middle East & North Africa, but second in Europe & Central Asia, fourth in South Asia and in sub-Saharan Africa, fifth in Latin America & Caribbean and (surprisingly) sixth in North America. They were third in countries classed by the World Bank as lower- or upper-middle-income, but fourth in low-income countries and fifth in those classed as high income. The association between headache and socioeconomic status has never been clear! GBD is wholly dependent on data. It applies highly sophisticated modelling to fill data gaps, “borrowing strength between locations and over time” [3]. But extrapolations from nearby countries to those where data are sparse or totally lacking is a process that cannot be free from uncertainty (evidenced by the wide uncertainty intervals around estimates for headache disorders [Table 1]). Not too much should be made of these variations. The level-3 grouping of headache disorders in GBD2019 includes only specific diseases: migraine and tension-type headache (TTH), each with medication-overuse headache (MOH) as a sequela factored in according to the proportion of MOH attributed to it [3]. Low back pain, on the contrary, is a symptom. It ought to, and hopefully will in future iterations of GBD, be split according to its diverse aetiologies. Even at level 4 in IHME’s analyses – supposedly of specific disorders – low back pain remains as a listed single cause of YLDs, and inevitably is ranked first among all but young adult women (Table 2). Migraine remains second overall (both genders, all ages) but takes first place in young women as it did in GBD2016 [5] (Table 2). In fact, migraine is top cause of DALYs in young women (Table 3), a finding, surely, of profound significance. No other disease, communicable or non-communicable, is responsible for more years of lost healthy life in young women, notwithstanding that migraine causes no premature mortality.
Table 2

GBD2019: Top level-4 causes of global disability (expressed as years lived with disability [YLDs]) by gender and age (data from [3, 4])

GenderAge range (years)RankCause% of total YLDs [uncertainty interval]
BothAll1Low back pain7.4 [6.2–8.7]
2Migraine4.9 [0.8–10.1]
3Age-related hearing loss4.7 [3.8–5.7]
15–491Low back pain7.6 [6.1–9.3]
2Migraine7.3 [1.1–15.1
3Major depression5.8 [4.3–7.5]
MaleAll1Low back pain7.0 [5.8–8.2
2Age-related hearing loss5.2 [4.3–6.4]
3Diabetes type 24.7 [4.0–5.4]
4Migraine4.1 [0.7–8.3]
15–491Low back pain7.8 [6.3–9.6]
2Migraine6.3 [1.1–12.8]
3Major depression5.2 [3.8–6.7]
FemaleAll1Low back pain7.7 [6.5–9.2]
2Migraine5.5 [0.9–11.6]
3Other musculoskeletal5.0 [3.8–6.4]
15–491Migraine8.0 [1.2–16.7]
2Low back pain7.4 [5.9–9.1]
3Major depression6.2 [4.6–8.2]
Table 3

GBD2019: Top level-4 causes of global lost healthy life (expressed as disability-adjusted life years [DALYs]) among young adult women (data from [3, 4])

RankCause% of total DALYs [uncertainty interval]
1Migraine4.9 [0.7–10.6]
2Low back pain4.5 [3.4–5.6]
3Major depression3.8 [2.7–4.9]
GBD2019: Top level-4 causes of global disability (expressed as years lived with disability [YLDs]) by gender and age (data from [3, 4]) GBD2019: Top level-4 causes of global lost healthy life (expressed as disability-adjusted life years [DALYs]) among young adult women (data from [3, 4]) New to GBD2019 were bias adjustments to make allowance for low-quality sampling and survey methods, and for a range of other methodological deficiencies in data sources [4]. This is an important development, since epidemiological methods in headache have improved over the last decade [6], and case definitions have changed over the last two [7, 8]. These, too, were factors contributing to the wide uncertainty intervals. Also as a methodological innovation, GBD2019 took separate account of definite and probable migraine and of definite and probable TTH [8], using individual participant data from studies in 19 countries on frequency and duration of episodes to estimate proportions of time in ictal state for each [4]. The authors of the GBD2019 report wrote: “The prominent position of headache disorders in the DALY rankings in the 10-24-year and 25-49-year age groups has received little attention in global health policy debates” [3]. A similar message has been our repeated cri de coeur [5, 9–12]. They added: “While there is no cure for these disorders, there are effective symptomatic and preventive treatments available.” This, of course, is not a revelation in headache circles, but outside them it appears still to be so. Remediability is the crucial issue in claims for priority in health care, especially when there is strong evidence of cost-effectiveness [13]. The disability burden of headache disorders – particularly of migraine, by far the principal contributor [3] – is concentrated among those of productive age. It is this factor that keeps headache high among the causes of YLDs (and DALYs) in less wealthy countries, where shorter life expectancies raise the population proportions of young adults. It is this, also, that adds – or should add – a dimension of mind-focusing concern for policy makers everywhere [5, 14].
  10 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

2.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.

Authors: 
Journal:  Cephalalgia       Date:  2018-01       Impact factor: 6.292

Review 3.  The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations from the Global Campaign against Headache.

Authors:  Lars Jacob Stovner; Mohammed Al Jumah; Gretchen L Birbeck; Gopalakrishna Gururaj; Rigmor Jensen; Zaza Katsarava; Luiz Paulo Queiroz; Ann I Scher; Redda Tekle-Haimanot; Shuu-Jiun Wang; Timothy J Steiner
Journal:  J Headache Pain       Date:  2014-01-27       Impact factor: 7.277

4.  Headache disorders are third cause of disability worldwide.

Authors:  Timothy J Steiner; Gretchen L Birbeck; Rigmor H Jensen; Zaza Katsarava; Lars J Stovner; Paolo Martelletti
Journal:  J Headache Pain       Date:  2015-06-25       Impact factor: 7.277

5.  Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries.

Authors:  Mattias Linde; Timothy J Steiner; Dan Chisholm
Journal:  J Headache Pain       Date:  2015-02-18       Impact factor: 7.277

6.  GBD 2015: migraine is the third cause of disability in under 50s.

Authors:  Timothy J Steiner; Lars J Stovner; Theo Vos
Journal:  J Headache Pain       Date:  2016-11-14       Impact factor: 7.277

7.  Migraine is first cause of disability in under 50s: will health politicians now take notice?

Authors:  Timothy J Steiner; Lars J Stovner; Theo Vos; R Jensen; Z Katsarava
Journal:  J Headache Pain       Date:  2018-02-21       Impact factor: 7.277

8.  Migraine: the seventh disabler.

Authors:  Timothy J Steiner; Lars J Stovner; Gretchen L Birbeck
Journal:  J Headache Pain       Date:  2013-01-10       Impact factor: 7.277

9.  Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet Neurol       Date:  2018-11       Impact factor: 44.182

10.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

Authors: 
Journal:  Lancet       Date:  2020-10-17       Impact factor: 202.731

  10 in total
  56 in total

Review 1.  Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP.

Authors:  Diana N Krause; Karin Warfvinge; Kristian Agmund Haanes; Lars Edvinsson
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

2.  The first report of the Italian Migraine Registry (I-GRAINE).

Authors:  Piero Barbanti; Gabriella Egeo; Cinzia Aurilia; Giulia Fiorentini; Stefania Proietti; Carlo Tomino; Stefano Bonassi
Journal:  Neurol Sci       Date:  2022-07-08       Impact factor: 3.830

3.  The profile of headaches and migraine amongst medical students and its association to stress level, disability and self-management practices.

Authors:  Anuradha Thiagarajan; Noor Azah Aziz; Chai-Eng Tan; Noor Azimah Muhammad
Journal:  Malays Fam Physician       Date:  2022-05-25

4.  fMRI Findings in Cortical Brain Networks Interactions in Migraine Following Repetitive Transcranial Magnetic Stimulation.

Authors:  Kirill Markin; Artem Trufanov; Daria Frunza; Igor Litvinenko; Dmitriy Tarumov; Alexander Krasichkov; Victoria Polyakova; Alexander Efimtsev; Dmitriy Medvedev
Journal:  Front Neurol       Date:  2022-06-21       Impact factor: 4.086

5.  Delta opioid receptors in Nav1.8 expressing peripheral neurons partially regulate the effect of delta agonist in models of migraine and opioid-induced hyperalgesia.

Authors:  Zachariah Bertels; Isaac J Dripps; Pal Shah; Laura S Moye; Alycia F Tipton; Kendra Siegersma; Amynah A Pradhan
Journal:  Neurobiol Pain       Date:  2022-07-11

6.  Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study.

Authors:  Chia-Chun Chiang; Rashmi Halker Singh; Nim Lalvani; Ken Shubin Stein; Deborah Henscheid Lorenz; Christine Lay; David W Dodick; Lawrence C Newman
Journal:  Headache       Date:  2021-05-21       Impact factor: 5.887

7.  Editorial. Valuing headache's solution.

Authors:  T J Steiner; M Tinelli
Journal:  J Headache Pain       Date:  2021-06-10       Impact factor: 7.277

Review 8.  Acute and Preventive Management of Migraine during Menstruation and Menopause.

Authors:  Raffaele Ornello; Eleonora De Matteis; Chiara Di Felice; Valeria Caponnetto; Francesca Pistoia; Simona Sacco
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

9.  MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

Authors:  Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río
Journal:  J Headache Pain       Date:  2021-07-17       Impact factor: 7.277

Review 10.  Comorbidities of primary headache disorders: a literature review with meta-analysis.

Authors:  Valeria Caponnetto; Manuela Deodato; Paolo Martelletti; Alberto Raggi; Micaela Robotti; Maria Koutsokera; Valeria Pozzilli; Cristina Galati; Giovanna Nocera; Eleonora De Matteis; Gioacchino De Vanna; Emanuela Fellini; Gleni Halili; Daniele Martinelli; Gabriele Nalli; Serena Serratore; Irene Tramacere
Journal:  J Headache Pain       Date:  2021-07-14       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.